文献速递肝胆胰外科围术期管理与 ERAS

胰腺头部良性及低度恶性肿瘤:剜除术与胰十二指肠切除术的比较

Enucleation vs Pancreatoduodenectomy for Benign and Low-Grade Pancreatic Head Tumors.
PubMed 文献 · JAMA Surg · 2026-09-30

这项多中心回顾性队列研究经倾向性评分匹配217对患者,发现胰腺头部良性或低度恶性肿瘤行剜除术较胰十二指肠切除术的临床相关术后胰瘘更高(33.2% vs 10.6%),但主要并发症更少、住院更短、长期生活质量更优。

要点

  • 剜除术的临床相关胰瘘(CR-POPF)显著高于胰十二指肠切除术(33.2% vs 10.6%)。
  • 剜除术主要并发症和延迟胃排空更低,住院时间更短。
  • 肿瘤≤2.5 cm时剜除术的并发症优势最明显。

核心结论

  • 对胰腺头部良性及低度恶性肿瘤,剜除术的CR-POPF高于胰十二指肠切除术,但主要并发症、延迟胃排空、住院时间和长期生活质量更优。
  • 研究支持在技术可行时,尤其肿瘤≤2.5 cm,剜除术可作为可选方案。

研究设计与样本

  • 多中心回顾性队列研究,纳入4家中国高容量中心2015年1月1日至2024年12月31日患者,中位随访36个月,采用1:1倾向性评分匹配。
  • 共660例患者(剜除术297例,胰十二指肠切除术363例;女性355例[53.8%];中位年龄55.0岁[IQR 41.0-65.0]),匹配后形成217对。

主要发现

  • 剜除术的CR-POPF为33.2%(72/217),胰十二指肠切除术为10.6%(23/217);调整OR 4.22(95%CI 2.47-7.21;P<.001)。
  • 剜除术主要并发症为8.8%(19/217),胰十二指肠切除术为17.1%(37/217);调整OR 0.37(95%CI 0.20-0.70;P=.002)。
  • 剜除术延迟胃排空为4.6%(10/217),胰十二指肠切除术为25.3%(55/217);P<.001。
  • 剜除术中位住院9天(IQR 6-14),胰十二指肠切除术15天(IQR 11-22);P<.001。
  • 剜除术全球健康状况评分均值77.4(SD 13.7),胰十二指肠切除术62.1(SD 18.0);P<.001;新发糖尿病7.8%(20/257)vs 33.3%(98/294);P<.001;重返工作92.7%(191/206)vs 72.0%(121/168);P<.001。

关键数值与推荐

  • 主要终点为临床相关术后胰瘘(CR-POPF;国际胰腺外科研究组B级或C级)。
  • 次要终点包括主要并发症(Clavien-Dindo III级或以上)、延迟胃排空、住院时间、长期生活质量和New-onset diabetes。
  • 肿瘤≤2.5 cm时剜除术并发症优势最大:5.8%(6/104)vs 26.2%(17/65);交互作用P=.01。

临床怎么用

  • 对胰腺头部良性或低度恶性肿瘤,技术可行时可考虑剜除术以保留胰腺实质,尤其肿瘤≤2.5 cm。
  • 剜除术需警惕较高的CR-POPF风险,应加强围术期胰瘘管理。
  • 与胰十二指肠切除术相比,剜除术可能减少主要并发症、缩短住院并改善长期生活质量。

局限性

  • 回顾性队列设计可能残留混杂。
  • 匹配后肿瘤大小仍存在组间不平衡,需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pancreatic enucleation may offer a parenchyma-sparing alternative to pancreatoduodenectomy for benign and low-grade malignant pancreatic head tumors, but its perioperative risk-benefit profile relative to pancreatoduodenectomy remains incompletely defined. OBJECTIVE: To compare short-term outcomes and long-term quality of life after enucleation vs pancreatoduodenectomy for benign and low-grade malignant tumors of the pancreatic head and uncinate process. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, retrospective cohort study assessed patients undergoing enucleation or pancreatoduodenectomy for benign or low-grade pancreatic head or uncinate process tumors at 4 high-volume Chinese centers (January 1, 2015, to December 31, 2024; median follow-up, 36 months) with 1:1 propensity score matching. Data analysis was performed from March to May 2026. EXPOSURE: Pancreatic enucleation vs pancreatoduodenectomy. MAIN OUTCOMES AND MEASURES: The primary end point was clinically relevant postoperative pancreatic fistula (CR-POPF; International Study Group on Pancreatic Surgery grade B or C). Secondary end points included major complications (Clavien-Dindo grade III or higher), delayed gastric emptying, length of stay, long-term quality of life (European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire and 26-item Quality of Life Pancreatic Cancer Questionnaire), and new-onset diabetes. Tumor-to-main pancreatic duct distance was evaluated through stratified and multivariable analyses. RESULTS: Of 660 patients (297 undergoing enucleation and 363 undergoing pancreatoduodenectomy; 355 [53.8%] female; median [IQR] age, 55.0 [41.0-65.0] years), 217 matched pairs were formed. CR-POPF was higher after enucleation (72 [33.2%] vs 23 [10.6%]; adjusted odds ratio, 4.22; 95% CI, 2.47-7.21; P < .001). Major complications were lower (19 [8.8%] vs 37 [17.1%]; adjusted odds ratio, 0.37; 95% CI, 0.20-0.70; P = .002) as was delayed gastric emptying (10 [4.6%] vs 55 [25.3%]; P < .001). Median (IQR) stay was 9 (6-14) vs 15 (11-22) days (P < .001). A total of 551 patients (83.5%) completed quality-of-life assessment; enucleation was associated with higher global health status (mean [SD] scores, 77.4 [13.7] vs 62.1 [18.0]; P < .001), lower new-onset diabetes (7.8% [20 of 257] vs 33.3% [98 of 294]; P < .001), and higher return to work (92.7% [191 of 206] vs 72.0% [121 of 168]; P < .001). Enucleation's complication advantage was greatest for tumors 2.5 cm or smaller (5.8% [6 of 104 patients] vs 26.2% [17 of 65 patients]; P for interaction = .01). CONCLUSIONS AND RELEVANCE: In this multicenter cohort study, enucleation for benign and low-grade pancreatic head tumors was associated with higher CR-POPF than pancreatoduodenectomy but fewer major complications, less delayed gastric emptying, shorter hospitalization, and superior long-term quality of life. These findings support enucleation as a viable option when technically feasible, particularly for tumors 2.5 cm or smaller; residual tumor size imbalance after matching warrants prospective confirmation.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Yao Z, Gao Y, Wang W, et al. Enucleation vs Pancreatoduodenectomy for Benign and Low-Grade Pancreatic Head Tumors. JAMA Surg. 2026. PMID: 42814443. doi:10.1001/jamasurg.2026.4498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。